On March 15, 2017, Tatiana Y. Lin, M.A., KHI Senior Analyst and Strategy Team Leader, provided neutral testimony on House Bill 2152 to the House Committee on Health and Human Services. The bill would, among other things, authorize hemp treatments for certain medical conditions.
During the testimony, KHI discussed findings and recommendations from its 2015 health impact assessment (HIA) Potential Health Effects of Legalizing Medical Marijuana in Kansas.
Access these publications in the Documents & Downloads section.
While KHI was presenting testimony on this bill, Representatives John Eplee, Ronald Ellis, Steven Crum and Abraham Rafie reviewed documents provided by KHI to supplement the testimony about the research KHI has conducted on potential health effects of medical marijuana.